Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jaguar Health, Inc. - Common Stock
(NQ:
JAGX
)
0.5800
-0.0250 (-4.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
January 22, 2026
Via
ACCESS Newswire
Here are the top movers in Tuesday's session.
↗
January 20, 2026
Via
Chartmill
Unusual volume stocks are being observed in Tuesday's session.
↗
January 20, 2026
Via
Chartmill
Tuesday's session: top gainers and losers
↗
January 20, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
January 20, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
January 20, 2026
Via
Chartmill
Which stocks are moving after the closing bell on Monday?
↗
January 19, 2026
Via
Chartmill
Get insights into the top gainers and losers of Friday's after-hours session.
↗
January 16, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Friday?
↗
January 16, 2026
Via
Chartmill
Curious about the most active stocks on Friday?
↗
January 16, 2026
Via
Chartmill
The Surge In Jaguar Health Stock: What's Happening Now?
↗
January 16, 2026
Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty.
Via
Benzinga
Keep an eye on the top gainers and losers in Friday's session.
↗
January 16, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
January 16, 2026
Via
Chartmill
Get insights into the top gainers and losers of Friday's pre-market session.
↗
January 16, 2026
Via
Chartmill
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
January 14, 2026
Via
ACCESS Newswire
Unusual volume stocks are being observed in Tuesday's session.
↗
January 13, 2026
Via
Chartmill
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
January 12, 2026
Via
ACCESS Newswire
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
January 06, 2026
Via
ACCESS Newswire
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
January 02, 2026
Via
ACCESS Newswire
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
December 15, 2025
Via
ACCESS Newswire
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
December 10, 2025
Via
ACCESS Newswire
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
December 08, 2025
Via
ACCESS Newswire
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
December 02, 2025
Via
ACCESS Newswire
Get insights into the top gainers and losers of Monday's after-hours session.
↗
November 24, 2025
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
November 24, 2025
Via
ACCESS Newswire
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
November 20, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
November 19, 2025
Via
Benzinga
Tuesday's after hours session: top gainers and losers
↗
November 18, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
November 17, 2025
Via
ACCESS Newswire
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
November 14, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
